Opportunities to enhance protections for individualized interventions involving gene-editing

The revelation of the previously unreported tragic death of a 6-year-old girl in Shanghai who received an experimental gene-edited intervention stands in stark contrast to the excitement surrounding the successful use of another experimental gene-edited intervention in an infant boy in Philadelphia just about a year earlier.1,2 Shrouded in secrecy, fueled by parental funding, and involving a flawed consent process, the Shanghai case casts a shadow on the budding field of personalized medicine using gene-editing.